InnoCare Pharma HK$3.04 billion share placement
We advised InnoCare Pharma in the placement of new shares
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Youdao $238 million equity follow-on offering
We advised Youdao on its offering of ADSs
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Venus Medtech HK$1.4 billion placing of new H shares
We advised Venus Medtech (Hangzhou) on its placement of new shares
CureVac $450 million public offering
We advised CureVac on the equity offering
Silvergate Capital $287.5 million follow-on offering
We advised the underwriters in connection with the equity offering
Innovent Biologics HK$4.73 billion placement of shares
We advised the joint placing agents in connection with the equity offering
Perion Network $66 million follow-on offering
We advised Perion, whose shares are listed on Nasdaq and the Tel Aviv Stock Exchange
iQIYI $1.5 billion concurrent convertible notes and equity offerings
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by iQIYI, Inc. of $800 million aggregate principal amount of its 4.00%…